All
Experimental Treatment Shows Promise for Certain Cases of Advanced NSCLC
September 23rd 2020There is no approved treatment that targets the KRAS p.G12C mutation that drives some cancers like non-small cell lung cancer. But a recent study shows how the experimental drug sotorasib sparked responses in some patients with advanced non-small cell lung cancer that harbored the mutation.
Lynparza Significantly Improves Survival in Subset of Patients with Metastatic Prostate Cancer
September 23rd 2020The PARP inhibitor Lynparza reduced the risk for death by 31% in men with metastatic castration-resistant prostate cancer compared with Xtandi or Zytiga plus the corticosteroid prednisone.
Tecentriq Combo Improves Response Rates in Early TNBC, Regardless of PD-L1 Status
September 22nd 2020Findings from a randomized phase 3 study showed that adding neoadjuvant Tecentriq to a chemotherapy regimen of Abraxane, Adriamycin and Cytoxan in patients with stage 2 or 3 triple-negative breast cancer significantly improved pathologic complete responses, compared with placebo plus chemotherapy.